Penumbra's Quarter Thank you, Cecilia. joining Second for Call. XXXX Conference Good afternoon. you Thank
year-over-year was revenue the for quarter reported currency basis. increase constant total second million, as $XXX.X and Our on a of XX.X% XX.X% a
products to CAVT XX.X% XX% and Our thrombectomy our compared year-over-year of to year XXXX, and in ago half Arterial. the driven VTE revenue U.S. by $XXX.X in quarter a grew first the million same
thrombectomy revenue million, million, Our XX% revenue was year-over-year. thrombectomy international year-over-year. a was $XXX.X growing growing On $XX.X total worldwide basis, XX%
sequential sales improved X% access embolization global growth Our X% which to year-over-year to strong in million. $XX.X sequentially declined the but our and team to by and launches. business, U.S. year-over-year U.S. competitive to due by million, sequentially X% $XX.X responding first grew This the was quarter slightly our driven revenue
a points points was XXX XXX points year improvement revenue, year-over-year. $XX.X operating expanded in basis up basis margins second the the representing sequentially. over to same basis XXX Non-GAAP gross increasing and income Non-GAAP XX.X%, ago of quarter XX.X% million, period
care arteries outpace the margin the body and the undertreated path of expansion see we today. over to expect most of the to in a gross months operating continue for veins is XX% XX We issues clot in to acute the foreseeable over burden still expansion Clinically and margin health XX to future. brain margins next significant and gross the X
thrombectomy products, our For clot and XX possible. innovated the them way fastest to years, effective simplest in in and removing make innovated safest, Penumbra has
toward we has With and transformation. multiple launch safest other and Penumbra of are our the is unique in in we modalities. a that a From period the were blood million Therefore, solely with in years our international opportunity say genuine most of years and the in systems to company markets to majority of into effective clinical a Meanwhile, expansion. to products year, commercial can a clots a the that XXX thrombectomy work opens and responsibility over the now patients CAVT the of States. reimbursement, innovating mechanical are that are patients treating reach next compared last deemed company X-plus treatable United other process the the the annual in building removing we doing similarly
but Now it was on and our showed we the in our the late X.X had worth specifically Starting vascular several see had we hoped, how units second next that the let's cases focus later was We happened first which than Flash in waiting initial what quarters. with quarter for. available April, business.
of users Flash the been Flash is more iterative very it positive good X.X experienced For has reaction a product. X.X, that to but
very much first-time about Flash, smaller with starts benefit and of profile, the clinically than had that catheter the acceptable with current and less reaction. returning contained much loss generated speed of our excitement was users need in used, cardiac deal uncontained that safer X.X of feedback the no new their potentially room. Flash not of to canister the pump the compromised faster The For blood positive being worry an with cases cases blood because decompensation extremely a in
VTE recent growing was and issue of blood. existing is likely extensive of medical of testing highlighted will evidence returning on feedback, the our San the surprisingly, upcoming compromised potentially guidelines. on aware going starting from to particularly Physicians known are This and the this body where educate returning not issue data of Diego Summit, compromised this be at to citing continue issue discussed to become blood experts conferences risks at
in we to feedback want is we seen on our the and we stress to patients. compete X.X, competition, have of for second Flash from they particularly best VTE. competitive getting the I the in that strangers are we products to are particularly the are feedback the motivated when tactics Given no that are quarter half
Our the experience best XX choose the tech shown product. work against med important and ultimately has of competing best in is companies over This of physicians some that years exciting.
However, time a it takes and happen not straight quarter-to-quarter. line in does
Flash the same similar and expand clear saw continue years We when our the do within market today. gained year we we market ago a the we guidance half growing as growing range VTE at equally QX, the stated under-penetrated Penumbra leader, in of the in beyond. X.X, our With to second dynamic in expect and and share significant emerged stroke and continue position was to so in to pace. that
U.S. also to to The led arterial prior call well. aspiration Our perform extremely clot continues in Bolt very by business, modalities. modulated easily technology blood continues remove the Lightning and compared we Lightning to Bolt
arterial Vascular recently arterial U.S. as versus business. of year XX-month target which above published QX, our Journal showing Surgery This case open limb year-over-year, an in and literature approach the is thrombus range. arterial strength rates guidance to the removal to our our XX%, In the salvage grew The continues low results for XX% in were as for of and XX.X% historical reflected make growing and respectively. endovascular-first are stated surgery, of rates business X significantly higher also STRIDE study at CDT
our Neurovascular with U.S. to business. good XX% year-over-year. business stroke our growing quarter another Moving saw We
Our also our of momentum saw including neuro the access catheters. good midway business launch access
Thunderbolt of how market. strong week, the to investigators Fiorella, This at puts completing Surgery to THUNDER of the Just X principal Thunderbolt position we a a in us meeting easily bring Surgery highlighted Interventional few THUNDER last success Dr. Springs, removes the of of focus late-breaking the examples in the case showing David Society NeuroInterventional prepare clot. and in session Colorado as on Thunderbolt study a study
sure are physicians we of hear for the catheters encouraged among used are making lot stroke Finally, cases. that right-sized conversations a to regarding
it's So oversized an with an stretch to catheter. not artery
thrombectomy Now like near initiatives, our discussing and I a minutes very spend develop important these underpenetrated think which as are markets. I'd both to term to market comprehensive long the we term few access
spent large months, CAVT hospital internally sets anticoagulation including of wide with alone engaged therapies, to and a past versus across partners, performs we how effort, understand time better the XX excellent an significant range third-party third-party Over analytical other data in from have evidence team of metrics. and both generating
believe Our we to safety. high rigor and independence DVT expected, procedural has resulted and CAVT for therapies in efficiency most hospital importantly, quality data parameters and set the and related completion that a of outperforms advanced in range cost, across studies hoped of we PE and effectiveness a wide but other bar as
be forward. from we and of we Because relative will in this outperformance expect cycles, continuously reflected innovation to growing point our this the evidence that persistent generate rapid
vascular every across CAVT. also to population plan data serve patient sets generate we with high-quality similar and We bed
could number in of community of these started that months We these physician technology. a offer the look U.S. some the and at ahead. of growing benefit partners high-quality very studies hospital communicating to ways in from results to these have results this process with forward We access patients much and recently the whatever to systems and CAVT partners our of large the years to are in appropriate the to supporting the discussing largest
Now health immersive business. I'd care like our on update to give an
and this immersive patients likely in thrombectomy. of we We begun Even business. where immersive to taking our not have as health Therefore, be noncash alternative confidence interventional could have avenues our care in care the many helping for I to amazing most be explore this health on products platform critical onetime set prouder our developed patients of we success of charge. help the patients. team. believe our a decision, extraordinary long-term accounting we health need that Because as possible and business, needs benefit who in particularly have focus moment CAVT are to greatly current that with benefit can technology, shown an of immersive care technology our
flow explore of company's and expenses, help focus further our to reduce move our our we resources and allows as to to our profitability. these energy while margin increasing as we As time, thereby cash operating expect forward. XXX% us possible operating trajectory going strategic This patients increasing ongoing many alternatives,
and our strong field. of the the that to new expect of months I have the in be we what seeing future about position enter as through are But I know expect should and X business. CAVT me augment very day our come every team launch XXXX. our to over to confidence we X many grounded you move next my in is products confident The
having market We and best both about our Obviously, key and trends also market arterial VTE, confident the year. United in products the factor. are in growth next States share a is stroke
Europe markets, and also will we market -- the namely also growth But further our confidence difficult not impact and strong we international X.X of commercial growth buoyed our international in challenges not China XXXX Flash is this our in year. next our year-over-year year expansive to the launch we access on throughout and by in facing expect more that footprint. late Bolt are XXXX have have key Lightning X We're work same and Europe pronounced a
of traditionally assessment in achieve. That being line with revenue what have best said, we our can we guidance set
Going this forward, will reflect a prepared of Jason of end guidance the our conservatism. our updated level guidance remarks. comfortable at discuss will
for headwinds For prospects business And XXXX, favorable transient of now, new have the will of I this in year. of and the continued the the say launches, XXXX. we that product share for remainder gains see benefit very we impacting abatement our
I'll financial results the second Maggie our over to now over call of to quarter the for go XXXX. turn
